BACKGROUND: Persistent pathologic mediastinal nodal involvement after induction chemotherapy and surgical resection is a negative prognostic factor for stage III-N2 non-small cell lung cancer patients. This population has high rates of local-regional failure and distant failure, yet the effectiveness of additional therapies is not clear. We assessed the role of consolidative therapies (postoperative radiation therapy and chemotherapy) for such patients. METHODS: In all, 179 patients with stage III-N2 non-small cell lung cancer at MD Anderson Cancer Center were treated with induction chemotherapy followed by surgery from 1998 through 2008; 61 patients in this cohort had persistent, pathologically confirmed, mediastinal nodal disease, and were treated with postoperative radiation therapy. Local-regional failure was defined as recurrence at the surgical site or lymph nodes (levels 1 to 14, including supraclavicular), or both. Overall survival was calculated using the Kaplan-Meier method, and survival outcomes were assessed by log rank tests. Univariate and multivariate Cox proportional hazards models were used to identify factors influencing local-regional failure, distant failure, and overall survival. RESULTS: All patients received postoperative radiation therapy after surgery, but approximately 25% of the patients also received additional chemotherapy: 9 (15%) with concurrent chemotherapy, 4 (7%) received adjuvant sequential chemotherapy, and 2 (3%) received both. Multivariate analysis indicated that additional postoperative chemotherapy significantly reduced distant failure (hazard ratio 0.183, 95% confidence interval: 0.052 to 0.649, p=0.009) and improved overall survival (hazard ratio 0.233, 95% confidence interval: 0.089 to 0.612, p=0.003). However, additional postoperative chemotherapy had no affect on local-regional failure. CONCLUSIONS: Aggressive consolidative therapies may improve outcomes for patients with persistent N2 disease after induction chemotherapy and surgery.
BACKGROUND: Persistent pathologic mediastinal nodal involvement after induction chemotherapy and surgical resection is a negative prognostic factor for stage III-N2 non-small cell lung cancerpatients. This population has high rates of local-regional failure and distant failure, yet the effectiveness of additional therapies is not clear. We assessed the role of consolidative therapies (postoperative radiation therapy and chemotherapy) for such patients. METHODS: In all, 179 patients with stage III-N2 non-small cell lung cancer at MD Anderson Cancer Center were treated with induction chemotherapy followed by surgery from 1998 through 2008; 61 patients in this cohort had persistent, pathologically confirmed, mediastinal nodal disease, and were treated with postoperative radiation therapy. Local-regional failure was defined as recurrence at the surgical site or lymph nodes (levels 1 to 14, including supraclavicular), or both. Overall survival was calculated using the Kaplan-Meier method, and survival outcomes were assessed by log rank tests. Univariate and multivariate Cox proportional hazards models were used to identify factors influencing local-regional failure, distant failure, and overall survival. RESULTS: All patients received postoperative radiation therapy after surgery, but approximately 25% of the patients also received additional chemotherapy: 9 (15%) with concurrent chemotherapy, 4 (7%) received adjuvant sequential chemotherapy, and 2 (3%) received both. Multivariate analysis indicated that additional postoperative chemotherapy significantly reduced distant failure (hazard ratio 0.183, 95% confidence interval: 0.052 to 0.649, p=0.009) and improved overall survival (hazard ratio 0.233, 95% confidence interval: 0.089 to 0.612, p=0.003). However, additional postoperative chemotherapy had no affect on local-regional failure. CONCLUSIONS: Aggressive consolidative therapies may improve outcomes for patients with persistent N2 disease after induction chemotherapy and surgery.
Authors: S M Keller; S Adak; H Wagner; A Herskovic; R Komaki; B J Brooks; M C Perry; R B Livingston; D H Johnson Journal: N Engl J Med Date: 2000-10-26 Impact factor: 91.245
Authors: Michael T Jaklitsch; James E Herndon; Malcolm M DeCamp; William G Richards; Parvesh Kumar; Mark J Krasna; Mark R Green; David J Sugarbaker Journal: J Surg Oncol Date: 2006-12-01 Impact factor: 3.454
Authors: R Bueno; W G Richards; S J Swanson; M T Jaklitsch; J M Lukanich; S J Mentzer; D J Sugarbaker Journal: Ann Thorac Surg Date: 2000-12 Impact factor: 4.330
Authors: B Dautzenberg; R Arriagada; A B Chammard; A Jarema; M Mezzetti; K Mattson; J L Lagrange; C Le Pechoux; B Lebeau; C Chastang Journal: Cancer Date: 1999-07-15 Impact factor: 6.860
Authors: Giorgio V Scagliotti; Ugo Pastorino; Johan F Vansteenkiste; Lorenzo Spaggiari; Francesco Facciolo; Tadeusz M Orlowski; Luigi Maiorino; Martin Hetzel; Monika Leschinger; Carla Visseren-Grul; Valter Torri Journal: J Clin Oncol Date: 2011-11-28 Impact factor: 44.544
Authors: R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal Journal: N Engl J Med Date: 1994-01-20 Impact factor: 91.245
Authors: Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: D C Betticher; S-F Hsu Schmitz; M Tötsch; E Hansen; C Joss; C von Briel; R A Schmid; M Pless; J Habicht; A D Roth; A Spiliopoulos; R Stahel; W Weder; R Stupp; F Egli; M Furrer; H Honegger; M Wernli; T Cerny; H-B Ris Journal: Br J Cancer Date: 2006-04-24 Impact factor: 7.640
Authors: Anurag K Singh; Mark Hennon; Sung Jun Ma; Todd L Demmy; Anthony Picone; Elizabeth U Dexter; Chumy Nwogu; Kristopher Attwood; Wei Tan; Gregory M Hermann; Simon Fung-Kee-Fung; Harish K Malhotra; Sai Yendamuri; Jorge A Gomez-Suescun Journal: BMC Cancer Date: 2018-11-29 Impact factor: 4.430